Abstract：
OBJECTIVE: This study aimed to reveal the role of preoperative main pancreatic duct (MPD) stent placement in reducing the intraoperative main pancreatic duct injury rate and the incidence of postoperative pancreatic leakage following pancreatic tumor enucleation.
METHODS: A retrospective cohort analysis was performed for all patients with benign/borderline pancreatic head tumors who were treated with enucleation. The patients were divided into two groups (standard vs. stent) depending on whether they underwent main pancreatic duct stent placement prior to surgery.
RESULTS: Thirty-three patients were finally included in the analytical cohort. Compared with the standard group, patients in the stent group had a shorter distance between tumors and main pancreatic duct (p=0.01) and presented with larger tumors (p<0.01). The rates of POPF (grade B&C) were 39.1% (9/23) and 20% (2/10) in the standard and stent groups, respectively (p<0.01). Major postoperative complications occurred more frequently in the standard group than in the stent group (14 versus 2; p<0.01). No significant differences in mortality, in-hospital stay or medical cost were observed between the two groups (p>0.05).
CONCLUSIONS: MPD stent placement prior to surgery may facilitate pancreatic tumor enucleation, minimize MPD injury and decrease the occurrence of postoperative fistula.
METHODS: A retrospective cohort analysis was performed for all patients with benign/borderline pancreatic head tumors who were treated with enucleation. The patients were divided into two groups (standard vs. stent) depending on whether they underwent main pancreatic duct stent placement prior to surgery.
RESULTS: Thirty-three patients were finally included in the analytical cohort. Compared with the standard group, patients in the stent group had a shorter distance between tumors and main pancreatic duct (p=0.01) and presented with larger tumors (p<0.01). The rates of POPF (grade B&C) were 39.1% (9/23) and 20% (2/10) in the standard and stent groups, respectively (p<0.01). Major postoperative complications occurred more frequently in the standard group than in the stent group (14 versus 2; p<0.01). No significant differences in mortality, in-hospital stay or medical cost were observed between the two groups (p>0.05).
CONCLUSIONS: MPD stent placement prior to surgery may facilitate pancreatic tumor enucleation, minimize MPD injury and decrease the occurrence of postoperative fistula.
摘要：
目的：本研究旨在揭示术前主胰管（MPD）支架置入对降低胰腺肿瘤摘除术后术中主胰管损伤率和术后胰漏发生率的作用。
方法：对所有接受摘除术治疗的良性/交界性胰头肿瘤患者进行回顾性队列分析。将患者分为两组(标准与支架），取决于他们在手术前是否接受了主胰管支架置入。
结果：33例患者最终被纳入分析队列。与标准组相比，支架组患者肿瘤与主胰管之间的距离较短(p=0.01),肿瘤较大(p<0.01).标准组和支架组POPF(B&C级)发生率分别为39.1%(9/23)和20%(2/10),分别(p<0.01)。标准组术后并发症发生率高于支架组(14对2;p<0.01)。死亡率没有显着差异，观察两组患者的住院时间和医疗费用(p>0.05)。
结论：手术前放置MPD支架可能有助于胰腺肿瘤摘除术，减少MPD损伤，减少术后瘘的发生。
方法：对所有接受摘除术治疗的良性/交界性胰头肿瘤患者进行回顾性队列分析。将患者分为两组(标准与支架），取决于他们在手术前是否接受了主胰管支架置入。
结果：33例患者最终被纳入分析队列。与标准组相比，支架组患者肿瘤与主胰管之间的距离较短(p=0.01),肿瘤较大(p<0.01).标准组和支架组POPF(B&C级)发生率分别为39.1%(9/23)和20%(2/10),分别(p<0.01)。标准组术后并发症发生率高于支架组(14对2;p<0.01)。死亡率没有显着差异，观察两组患者的住院时间和医疗费用(p>0.05)。
结论：手术前放置MPD支架可能有助于胰腺肿瘤摘除术，减少MPD损伤，减少术后瘘的发生。
